Aevi Genomic Medicine — Merger or Acquisition (December 2019)
37 slides from Aevi Genomic Medicine's merger presentation, Dec 23, 2019
Slide 1: Establishing a leading, rare disease-focused biopharmaceutical company
Exhibit 99.1 Driven by Science Inspired by Hope Establishing a leading, rare disease-focused biopharmaceutical company to deliver impactful new medicines to patients December | 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and unc
Slide 3: Additional Information Concerning the Merger
Additional Information Concerning the Merger Additional Information about the Merger and Where to Find It In connection with the proposed merger with Aevi, Cerecor will file with the SEC a Registration Statement on Form S-4 containing a proxy statement/prospectus. The proxy statement/prospectus will
Slide 4: Cerecor Continues Transformation
Cerecor Continues Transformation Building a rare disease biotech company committed to developing innovative medicines in areas of high unmet need Advancing CERC-800s to NDA filings and FDA approvals over the next 18 to 24 months; potential PRVs could provide non-dilutive capital for R&D investment E
Slide 5: Cerecor and Aevi Have Entered Into a Merger Agreement
Cerecor (CERC) & Aevi (GNMX) Have Entered Into a Merger Agreement to Merge Propose to form a leading biopharmaceutical company focused on pediatric orphan diseases Rare disease programs establish robust pipeline with 6 addition of novel, first-in-class medicines + PRV-eligible, fast-to-market progra
Slide 6: Combined Company Well-Positioned to Deliver Innovative New Medicines
Combined Company Well-Positioned to Execute on Delivering Innovative New Medicines to Patients CERC-800s AEVI-007 AEVI-006 • Substrate replacement • Anti-IL-18 mAb for • mTORC1/2 inhibitor for therapies for CDGs auto-inflammatory diseases Lymphatic Malformations • 2 pivotal-ready programs • Phase 2-
Slide 7: Emerging Clinical-Stage, Rare Disease Pipeline
Emerging Clinical-Stage, Rare Disease Pipeline Programs in • Building a rare disease biotech company Orphan Diseases focused on developing innovative medicines with Significant • Opportunity for multiple novel product 6 Unmet Needs launches through 2023 Development Stage Mechanism Lead Upcoming Prog
Slide 8: Recent BD&L Improves Financials, Emphasizes Pipeline
Recent BD&L Improves Financials, Emphasizes Pipeline Sale of commercial assets provides cash and removes debt overhang, while novel asset acquisitions further strengthen pipeline and focus on R&D CERC BD&L Highlights GNMX BD&L Highlights Sale of pediatric commercial portfolio In-licensed two Phase 2
Slide 9: Management Team
Management Team Extensive experience in orphan drug development & commercialization Michael F. Cola Dr. Pericles Calias Chief Executive Officer Chief Scientific Officer 25+ Years Industry Experience 20+ Years Industry Experience • President of Specialty Pharmaceuticals, Shire plc • VP Global CMC & D
Slide 10: CERC-800s
CERC-800s Fast-to-market substrate replacement therapies for Congenital Disorders of Glycosylation
Slide 11: Congenital Disorders of Glycosylation (CDG)
Congenital Disorders of Glycosylation (CDG): Life-Threatening, Ultra-Orphan, Inborn Errors of Metabolism (IEMs) Autosomal recessive diseases that result in impaired glycoprotein production and function, but are treatable with substrate replacement therapy Glycosylation is essential for protein Facto
Slide 12: CERC-800s Substrate replacement therapies for CDGs
CERC-800s Substrate replacement therapies for CDGs Oral, small molecule, naturally-occurring monosaccharides used as standard-of-care for CDGs • Rapid onset of action OH OH • Safe and well-tolerated HO O HO O HO O • Documented clinical experience of efficacy HO OH HO OH HO OH • Symptoms return upon
Slide 13: CDG Addressable Markets & Commercial Opportunity
CDG Addressable Markets & Commercial Opportunity Opportunity for indication expansion to build a >$100mm franchise CDG Incidence Total Addressable Market Potential 1 in 50,000 to 100,000 with Label Expansion births annually Product Patients PPPY Revs CERC-801 1,000 $100,000 $100M CERC-802 500 $100,0
Slide 14: CDG FIRST Trial
CDG FIRST Trial: Retrospective Study to Accelerate Development & Approval of CERC-800s; Targeted NDA Filing(s) Starting in 2021 Multi-center, international, non-interventional, retrospective study of CDG patients who have been treated with unapproved sugar supplements North America Europe Retrospect
Slide 15: Key Upcoming CERC-800s Milestones
Key Upcoming CERC-800s Milestones Multiple value-generating inflection points over the next 12 to 18 months • FDA meetings to define pathway to NDA submission and approval – Briefing package expected to include data collected under CDG FIRST – Determine pivotal study requirement and/or design Progra
Slide 16: AEVI-007
AEVI-007 Phase 2-ready, anti-IL-18 monoclonal antibody for orphan auto-inflammatory diseases
Slide 17: IL-18-Mediated Autoimmune Disorders
IL-18-Mediated Autoimmune Disorders IL-18 is a pro-inflammatory cytokine produced by macrophages, stimulating production/release of IFNγ and regulating many immune processes Elevated Serum IL-18 Levels in AOSD Patients IL-18bp Response Rates 1000000 80 100000 10000 60 * 18 (pg/ml) 1000 40 100 Serum
Slide 18: Elevated IL-18 is Associated with Poor Prognosis in Myeloma
Elevated IL-18 is Associated with Poor Prognosis in Myeloma IL-18 blockade has the potential to significantly prolong survival in multiple myeloma patients with elevated IL-18 levels • Patients with low IL-18 have IL-18 levels are elevated in many MM patients significantly longer median and correlat
Slide 19: AEVI-007: Anti-IL-18 mAb Developed by Medimmune
AEVI-007: Anti-IL-18 mAb Developed by Medimmune A high affinity, neutralizing monoclonal antibody against IL-18 • Potent and durable IL-18 inhibition – Evaluated in Phase 1 SAD for COPD – IV doses of 10, 30, 100, 300 or 1000 mg – Safe and well-tolerated (n = 31) • Phase 2-ready asset – 13-week monke
Slide 20: AEVI-007 Development Plan
AEVI-007 Development Plan Prioritize lower-risk, less capital intensive development strategy • Both programs are de-risked by preclinical and clinical proof-of-concept • Precision medicine approach using disease biomarkers is highly efficient and further de-risks clinical programs • Opportunity to e
Slide 21: AEVI-006
AEVI-006 Phase 2-ready, mTORC1/2 small molecule inhibitor for complex Lymphatic Malformations
Slide 22: mTOR Pathway in Lymphatic Malformations
mTOR Pathway in Lymphatic Malformations (LM) Lymphatic Malformations are a family of potentially life-threatening congenital diseases of the lymphatic system • Orphan disease(s) with combined US mTORC1/2 pathway prevalence of 30,000 to 60,000 patients – Kaposiform Lymphangiomatosis (KLA) – Generaliz
Slide 23: Off-label Use of mTOR Inhibitor Sirolimus in LM
Off-label Use of mTOR Inhibitor Sirolimus in LM Open-label clinical studies support efficacy, however use is limited by tolerability issues and lack of FDA approval • Phase 2 trial enrolled patients with complicated vascular anomalies – Study enrolled patients with different subtypes of LM not contr
Slide 24: AEVI-006: mTORC1/2 Inhibitor Developed by Astellas
AEVI-006: mTORC1/2 Inhibitor Developed by Astellas High potency, 2nd generation, dual inhibitor of mTORC1/2 with potential for improved efficacy and tolerability • Phase 2-ready asset – 4-week nonclinical tox studies completed – Previously studied in Phase 1 MAD (n = 128) – Development discontinued
Slide 25: AEVI-002
AEVI-002 Anti-LIGHT monoclonal antibody in clinical studies for Severe Pediatric-Onset IBD
Slide 26: Elevated LIGHT is Associated with Active Inflammatory Disease
Elevated LIGHT is Associated with Active Inflammatory Disease A novel target for autoimmune disease identified via CHOP discovery • LIGHT (Lymphotoxin-like, exhibits Free LIGHT Levels in Pediatric Crohn’s Disease Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor express
Slide 27: AEVI-002: Anti-LIGHT mAb Partnered with KHK
AEVI-002: Anti-LIGHT mAb Partnered with KHK Clinical-stage, first-in-class monoclonal antibody against LIGHT, originally discovered by La Jolla Allergy Institute • Fully-human, IgG4 antibody with successfully completed Phase 1 SAD study in healthy volunteers – Demonstrated good safety up to 1200 mg
Slide 28: Key Financial Information
Key Financial Information (CERECOR
Slide 29: Financial & Investor Information
Financial & Investor Information Key financial highlights NASDAQ:CERC NASDAQ:GNMX • Share Price (as of 12/16/19) = $4.47 • Share Price (as of 12/16/19) = $0.14 – 52-week high = $7.66 – 52-week high = $1.31 – 52-week low = $2.71 – 52-week low = $0.11 • O/S = 45.8M • O/S = 64.8M • Market Cap (as of 12
Slide 30: Executive Summary
Executive Summary Unique potential for multiple drug approvals through 2023 • Execution on orphan pipeline to deliver value for patients and shareholders – Attractive commercial opportunities and 4 potential PRV awards from first-in-class medicines for diseases with no approved treatment options CER
Slide 31: Driven by Science Inspired by Hope
Driven by Science Inspired by Hope NASDAQ:CERC www.cerecor.com
Slide 32: Appendix
Appendix
Slide 33: AOSD Treatment Paradigm
AOSD Treatment Paradigm Currently there are no approved targeted therapies for AOSD in the US, and no interventional clinical trials underway • Fever, rash, pharyngitis, arthritis, Opportunity to target sub-population presenting liver disease and increased ferritin with significantly elevated serum
Slide 34: CERC-301: Phase I Results in nOH
CERC-301: Phase I Results in nOH Highlighting 20mg Dose 20mg dose results in +29.8mm Hg increase in SBP over placebo at 6-hour post- dose OST, while only increasing +7.6mm Hg while seated 20mg (n = 8) vs Placebo (n = 12) pre-dose vs 6-hours post-dose 155 Seated Standing +7.6 (–20.7) 135 (–42.9) SBP
Slide 35: CERC-301: A Pipeline Within a Product
CERC-301: A Pipeline Within a Product CERC-301’s differentiated profile expands addressable patient population to additional diseases characterized by low blood pressure Neurogenic Orthostatic Diabetic Orthostatic Intradialytic Hypotension Hypotension Hypotension (IDH) Estimated Patient Population E
Slide 36: Value of a Priority Review Voucher
Value of a Priority Review Voucher Recent PRV sales demonstrate stabilization in asset valuation Median purchase price = ~90mm 120 $110 $105 100 $95 $81 $80 80 60 40 20 0 2017 2018 2018 2019 2019 36| Reference: https://priorityreviewvoucher.org/
Slide 37: Preclinical Pipeline
Preclinical Pipeline Additional early-stage, preclinical programs leveraging novel approaches to diseases with high unmet needs • Potential for 3 new IND filings throughout 2020 Mechanism Lead Development Stage Program of Action Indication Discovery Lead Opt IND-Enabling CNS-Targeted Parkinson’s CER
Aevi Genomic Medicine — Merger or Acquisition (December 2019) on 6ix